Subscribe
istock-168586352_ll28
ll28 / iStockphoto.com
13 December 2018Biotechnology

FDA releases plan to boost biosimilars development

The US Food and Drug Administration (FDA) has announced new measures to advance the development of biosimilar medicines.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
FDA announces new measures to boost gene therapy innovation
16 January 2019   The US Food and Drug Administration has announced new policies to advance the development of safe and effective cell and gene therapies.
article
FDA to alter biosimilar ‘suffix’ policy
8 March 2019   The US Food and Drug Administration yesterday announced draft revisions to its policy on the naming of biosimilars, in an attempt to appease critics who say that renaming previously-licensed products is too expensive.
Americas
Diabetics to benefit under latest FDA biosimilar guidance
13 May 2019   The Food and Drug Administration has issued final guidance on the pathway for ‘interchangeable’ biosimilar products, in a bid to promote competition in the biologics market.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
FDA announces new measures to boost gene therapy innovation
16 January 2019   The US Food and Drug Administration has announced new policies to advance the development of safe and effective cell and gene therapies.
article
FDA to alter biosimilar ‘suffix’ policy
8 March 2019   The US Food and Drug Administration yesterday announced draft revisions to its policy on the naming of biosimilars, in an attempt to appease critics who say that renaming previously-licensed products is too expensive.
Americas
Diabetics to benefit under latest FDA biosimilar guidance
13 May 2019   The Food and Drug Administration has issued final guidance on the pathway for ‘interchangeable’ biosimilar products, in a bid to promote competition in the biologics market.

More on this story

Americas
FDA announces new measures to boost gene therapy innovation
16 January 2019   The US Food and Drug Administration has announced new policies to advance the development of safe and effective cell and gene therapies.
article
FDA to alter biosimilar ‘suffix’ policy
8 March 2019   The US Food and Drug Administration yesterday announced draft revisions to its policy on the naming of biosimilars, in an attempt to appease critics who say that renaming previously-licensed products is too expensive.
Americas
Diabetics to benefit under latest FDA biosimilar guidance
13 May 2019   The Food and Drug Administration has issued final guidance on the pathway for ‘interchangeable’ biosimilar products, in a bid to promote competition in the biologics market.

More features

President Trump 2.0: Five major areas to watch
China’s new policies on foreign investment in healthcare and biotech
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug